Evidence map›Paper›PMID 30335821›Full record

ArticlePloS one2018

Display of the HIV envelope protein at the yeast cell surface for immunogen development.

Elizabeth Mathew, Hong Zhu, Sara M Connelly, Mark A Sullivan, Matthew G Brewer, Michael S Piepenbrink, James J Kobie, Stephen Dewhurst, Mark E Dumont

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Yeast-mediated display: probingIranian journal of microbiology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Elizabeth MathewDepartment of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Hong ZhuDepartment of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Sara M ConnellyDepartment of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Mark A SullivanDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States of America.
Matthew G BrewerDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States of America.
Michael S PiepenbrinkInfectious Diseases Division, University of Rochester Medical Center, Rochester, NY, United States of America.
James J KobieInfectious Diseases Division, University of Rochester Medical Center, Rochester, NY, United States of America.
Stephen DewhurstDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States of America.
Mark E DumontDepartment of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.ORCID 0000-0002-9078-523X
University of Rochester Medical Center · US

Funding

Targeting IgM Memory to Establish Protective B Cell Responses to HIVR01AI117787 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2018
$2.7M
Yeast Genetic Approach to Enhance the Immunogenicity of HIV Envelope GlycoproteinR01AI102730 · NIAID · UNIVERSITY OF ROCHESTER · PI DUMONT, MARK E. · 2012 to 2015
$1.5M
NIAID NIH HHS R01 AI102730NIAID NIH HHS R01 AI117787
6 · The paper itself

Abstract

As a step toward the development of variant forms of Env with enhanced immunogenic properties, we have expressed the glycoprotein in the yeast surface display system in a form that can be subjected to random mutagenesis followed by screening for forms with enhanced binding to germline antibodies. To optimize the expression and immunogenicity of the yeast-displayed Env protein, we tested different approaches for cell wall anchoring, expression of gp120 and gp140 Env from different viral strains, the effects of introducing mutations designed to stabilize Env, and the effects of procedures for altering N-linked glycosylation of Env. We find that diverse forms of HIV envelope glycoprotein can be efficiently expressed at the yeast cell surface and that gp140 forms of Env are effectively cleaved by Kex2p, the yeast furin protease homolog. Multiple yeast-displayed gp120 and gp140 proteins are capable of binding to antibodies directed against the V3-variable loop, CD4 binding site, and gp41 membrane-proximal regions, including some antibodies whose binding is known to depend on Env conformation and N-linked glycan. Based on antibody recognition and sensitivity to glycosidases, yeast glycosylation patterns partially mimic high mannose-type N-glycosylation in mammalian cells. However, yeast-displayed Env is not recognized by some anti-Env antibodies sensitive to quaternary structure, suggesting either that the displayed protein exists in a monomeric state or that for these antibodies, yeast glycosylation in certain regions hinders recognition or access. Consistent with studies in other systems, reconstructed predicted unmutated precursors to anti-Env antibodies exhibit little affinity for the yeast-displayed envelope protein.

Indexed as

AIDS Vaccinesenv Gene Products, Human Immunodeficiency VirusGlycosylationHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HumansImmunogenicity, VaccineImmunologic TechniquesMutagenesis, Site-DirectedMutationProprotein ConvertasesProtein BindingSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAIDS Vaccinesenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120KEX2 protein, S cerevisiaeProprotein ConvertasesSaccharomyces cerevisiae Proteins

Identifiers

PMID30335821
PMCPMC6193675
OpenAlexW2897850056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.